Faculty of Medicine, Department of Dermatology, Cutaneous Lymphoma Clinic, Cairo University, Egypt.
Dermatol Ther. 2021 Jan;34(1):e14463. doi: 10.1111/dth.14463. Epub 2020 Nov 9.
The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis.
2019 年冠状病毒病（COVID-19）疫情在全球迅速蔓延。关于 COVID-19 感染和皮肤淋巴瘤的文献中没有足够的数据。本综述从皮肤淋巴瘤的角度阐明了迄今为止对 COVID-19 的了解。皮肤 T 细胞淋巴瘤（CTCL）的诊断并不代表病毒感染的易患因素，而且大多数 CTCL 患者的疾病呈惰性。然而，医生应该对侵袭性原发性皮肤淋巴瘤和晚期 CTCL 的患者保持警惕。在 COVID-19 大流行期间，应考虑对皮肤淋巴瘤采用不同的治疗策略。因此，非常有必要根据具体情况评估利弊比。
